Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc.
Bullboard Posts
User Avatar Image
(2146)
•••
Comment by jdstoxon Oct 16, 2018 2:50pm
134 Views
Post# 28812306

RE:RE:RE:RE:bevacizumab

RE:RE:RE:RE:bevacizumab"However, rationale for IA delivery and BBBO when delivering antibodies is lacking."

So, what does the above statement mean, digitel?

Sounds like a have-you-stopped-beating-your-wife type of statement.

I would suggest that the author of that question should read the Texas Tech Lockman BT2111 paper and the MedImmune paper.

He might find a little rationale right there, probably - not for BBBO, but for NOBBB - Not Opening the BBB.

I'll refrain from writing any NOBBB jokes, digitel.

jdstox

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities